NEW YORK (GenomeWeb News) – CytRx subsidiary RXi Pharmaceuticals has licensed short hairpin RNAi technology from Cold Spring Harbor Laboratory, CytRX said today.
 
Under the licensing agreement, RXi purchased a worldwide, non-exclusive license to the technology, which was developed by Cold Spring Harbor’s Gregory Hannon.
 
Hannon is a co-founder and member of RXi’s scientific advisory board.
 
Financial terms of the agreement were not released.

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have an account?
Login Now.

Researchers report using genotyping to tie together illegal ivory shipments and trace them back to a handful of cartels, the New York Times reports.

Researchers find that historical factors influence which genes are the most highly studied, the Atlantic reports.

The US National Science Foundation's new sexual harassment policy is to go into effect next month, according to Nature News.

In Nature this week: genomic ancestry analysis of Sardinians, current noncoding mutations in colorectal cancer, and more.